Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -130.24%-476K | -249.05%-1.65M | -379.20%-765K | 1,223.78%4.06M | -11.63%1.11M | 372.32%1.57M | 389.03%1.11M | 2,007.69%274K | 140.88%307K | 608.10%1.26M |
| Net income from continuing operations | -134.32%-1.11M | -122.51%-1.95M | 9.35%-1.2M | -260.28%-17.09M | -716.71%-14.42M | 56.74%-472K | 1.80%-875K | -33.13%-1.33M | -15.40%-4.74M | -15.66%-1.77M |
| Operating gains losses | ---- | ---- | ---- | 669.23%800K | 834.78%215K | 144.44%110K | 7,060.00%348K | 209.76%127K | -55.56%104K | -82.17%23K |
| Depreciation and amortization | -3.71%1.12M | -5.30%1.14M | -17.61%1.06M | 33.65%4.86M | 18.46%1.2M | 25.00%1.16M | 39.98%1.21M | 55.30%1.29M | 14.03%3.63M | 16.44%1.01M |
| Asset impairment expenditure | --0 | --0 | -57.89%48K | 2,196.04%13.34M | 2,135.46%12.99M | --0 | --238K | --114K | --581K | --581K |
| Remuneration paid in stock | -40.46%78K | 341.94%685K | -56.19%145K | 15.76%742K | 56.25%125K | -32.82%131K | -12.92%155K | 76.06%331K | 48.04%641K | -33.88%80K |
| Deferred tax | -175.00%-341K | -1,247.50%-539K | 34.86%-241K | -32.74%-2.23M | -451.14%-1.69M | 76.99%-124K | 93.46%-40K | -68.95%-370K | -125.40%-1.68M | 30.54%-307K |
| Other non cashItems | 427.61%534K | 52,100.00%520K | -44.23%348K | 93.86%1.93M | 276.61%1.47M | -166.80%-163K | -100.17%-1K | 367.81%624K | -0.30%993K | -57.06%389K |
| Change In working capital | -196.14%-896K | -2,145.95%-1.51M | -79.42%-924K | 121.45%1.71M | -1.45%1.22M | 358.89%932K | 114.54%74K | -228.11%-515K | 203.61%774K | 506.89%1.24M |
| -Change in receivables | ---- | 95.55%-47K | 15.51%-599K | -232.44%-792K | -102.08%-6K | 3,363.33%979K | -1,177.55%-1.06M | -392.98%-709K | --598K | --288K |
| -Change in prepaid assets | ---- | -639.13%-170K | 162.20%215K | 736.17%299K | 27.95%-116K | 1.71%356K | 70.51%-23K | 151.90%82K | ---47K | ---161K |
| -Change in payables and accrued expense | ---- | -211.73%-1.3M | -615.09%-546K | 507.99%2.21M | 20.02%1.34M | 42.08%-395K | 321.61%1.16M | -76.65%106K | --363K | --1.11M |
| -Change in other working capital | ---- | ---2K | 0.00%6K | ---- | ---- | ---- | ---- | 104.41%6K | ---140K | --0 |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -130.24%-476K | -249.14%-1.65M | -378.83%-764K | 1,223.78%4.06M | -11.63%1.11M | 372.32%1.57M | 389.03%1.11M | 2,007.69%274K | 140.88%307K | 608.10%1.26M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -57.44%-751K | 201.88%759K | 148.10%1.05M | 78.07%-3.65M | 91.54%-248K | 92.86%-477K | 83.43%-745K | 14.46%-2.18M | -122.84%-16.66M | -9.81%-2.93M |
| Capital expenditure reported | 21.38%-375K | 44.43%-414K | 74.81%-550K | 78.61%-3.65M | 92.59%-248K | 92.60%-477K | 85.65%-745K | -4.10%-2.18M | -132.94%-17.08M | ---3.35M |
| Net PPE purchase and sale | --32K | ---- | ---- | ---- | ---- | --0 | ---- | ---- | --0 | -141.07%-1.53M |
| Net business purchase and sale | ---- | ---- | ---- | 50.79%-500K | ---500K | ---- | ---- | ---- | 68.69%-1.02M | --0 |
| Net other investing changes | --0 | --1.14M | --1.6M | -65.23%500K | --0 | ---- | ---- | ---- | -52.40%1.44M | 61.63%1.94M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -57.44%-751K | 201.88%759K | 148.10%1.05M | 78.07%-3.65M | 91.54%-248K | 92.86%-477K | 83.43%-745K | 14.46%-2.18M | -122.84%-16.66M | -9.81%-2.93M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | -24.81%-1.13M | 787.59%4.66M | -97.45%52K | -107.19%-581K | -268.06%-1.04M | -45.88%-903K | -107.89%-677K | 509.02%2.04M | 420.88%8.08M | 157.84%620K |
| Net issuance payments of debt | -90.16%-715K | 447.37%198K | -59.03%1.1M | -81.21%1.72M | -155.39%-521K | -72.48%-376K | -100.57%-57K | 809.02%2.67M | 882.72%9.15M | 37.80%-204K |
| Net common stock issuance | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | --0 | ---- |
| Cash dividends paid | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Interest paid (cash flow from financing activities) | 18.32%-388K | 36.28%-404K | 32.85%-421K | -146.21%-2.21M | -86.51%-470K | -146.11%-475K | -190.83%-634K | -169.10%-627K | -46.41%-896K | ---252K |
| Net other financing activities | 53.85%-24K | -1,092.86%-139K | -12,340.00%-622K | 44.44%-95K | -104.83%-52K | 75.00%-52K | 101.22%14K | -104.50%-5K | 37.13%-171K | 107,700.00%1.08M |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | -24.81%-1.13M | 787.59%4.66M | -97.45%52K | -107.20%-582K | -268.23%-1.04M | -45.88%-903K | -107.89%-677K | 509.02%2.04M | 420.88%8.08M | 157.84%620K |
| Net cash flow | ||||||||||
| Beginning cash position | 1,023.13%4.52M | 4.88%752K | -29.23%414K | -93.39%585K | -63.70%596K | -95.78%402K | -87.67%717K | -93.39%585K | -54.83%8.85M | -87.21%1.64M |
| Current changes in cash | -1,313.40%-2.35M | 1,294.60%3.76M | 156.06%338K | 97.93%-171K | 82.78%-182K | 102.46%194K | -108.51%-315K | 104.34%132K | 23.06%-8.27M | 73.50%-1.06M |
| End cash Position | 262.58%2.16M | 1,023.13%4.52M | 4.88%752K | -29.23%414K | -29.23%414K | -63.70%596K | -95.78%402K | -87.67%717K | -93.39%585K | -93.39%585K |
| Free cash from | -177.58%-851K | -670.44%-2.07M | 31.17%-1.31M | 102.45%411K | 141.20%861K | 115.62%1.1M | 106.49%362K | 8.40%-1.91M | -107.50%-16.77M | 38.20%-2.09M |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.